Diabetes & Metabolism Journal

Review

Pharmacotherapy
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning: Jung A Kim, Hye Jin Yoo; Diabetes Metab J. 2025;49(4):525-541. Published online July 1, 2025; DOI: https://doi.org/10.4093/dmj.2025.0242

59,440 View
1,773 Download
31 Web of Science
44 Crossref

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.

Citations

Citations to this article as recorded by

Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
Epilepsia.2026; 67(3): 1246. CrossRef
Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation
Elsayed A. Elmorsy, Sameh Saber, Ahmed Y. Kira, Manal Mohamed Hatem, Mohammed Alorini, Suzan Awad AbdelGhany Morsy, Hamad Alsaykhan, Abdulaziz A. Alsalloom, Nahla B. Mohamed, Norah Suliman Alsoqih, Rabab S. Hamad, Youssef El-Sayed, Nagwa Mahmoud Ramadan,
Journal of Drug Delivery Science and Technology.2026; 118: 108078. CrossRef
Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
Nimet Yılmaz, Mehmet Bastemir
Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
Kwang Hyun Chung, Jaihwan Kim
The Korean Journal of Pancreas and Biliary Tract.2026; 31(1): 1. CrossRef
Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
Claudia Reytor-González, Martín Campuzano-Donoso, Gerardo Sarno, Martha Montalvan, Raquel Horowitz, Gianluca Rossetti, Vincenzo Pilone, Luigi Barrea, Giovanna Muscogiuri, Luigi Schiavo, Daniel Simancas-Racines
Nutrients.2026; 18(4): 553. CrossRef
Oral Administration of Crocus sativus Tepals Extract Restores High‐Fat Diet‐Induced Gut Dysbiosis and Modulates Intestinal Inflammation and Hepatic Lipid Metabolism
Biljana Bursać, Miloš Vratarić, Ljupka Gligorovska, Luisa Bellachioma, Ana Teofilović, Danijela Vojnović Milutinović, Camilla Morresi, Elisabetta Damiani, Tiziana Bacchetti, Ana Djordjevic
BioFactors.2026;[Epub] CrossRef
A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis
Suhasini Rallabandi, Mansi Sharma, Krishnamraju Kosuru, Rahul Kashyap
Cureus.2026;[Epub] CrossRef
The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity
Andro Koren, Luciana Koren
British Journal of Clinical Pharmacology.2026;[Epub] CrossRef
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan
Chronic Diseases and Translational Medicine.2026; 12(2): 100. CrossRef
Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)
Antonio Facciorusso, Edoardo G Giannini, Matteo Tacelli, Alberto Zanetto, Cristiano Spada, Ivo Boskoski, Manuele Furnari, Grazia Pennisi, Gabriele Capurso, Alessandro Vitello, Giovanni Marasco, Giovanni Sarnelli, Luca Frulloni, Marcello Maida
Digestive and Liver Disease.2026; 58(6): 737. CrossRef
Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions
Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed
Obesity Medicine.2026; 61: 100699. CrossRef
New generation anti-obesity drugs and bone health in postmenopausal women
Jana Tomasová Studýnková
Vnitřní lékařství.2026; 72(2): 104. CrossRef
Re-establishing alliances: “Old Friends” confronting obesity, inflammation, and stress-related psychiatric disorders
Luke W. Desmond, Christopher A. Lowry
Brain Behavior and Immunity Integrative.2026; 15: 100166. CrossRef
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Limosilactobacillus fermentum K8-Lb1 Postbiotic on Weight Management and Metabolic Health Outcomes
Ekaterina Papazova, Susanne Mitschke, Christiane Laue, Jürgen Schrezenmeir
Nutrients.2026; 18(8): 1174. CrossRef
Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
Uchechukwu Bethel Abioke, Isaac Baiden, Obiageri Ihuarulam Okeoma, Victoria Partey-Newman, Temitope Oluwatosin Adewale, Shadrach Oluchi Onyekezini, Ijeoma Linda Okwuowulu
Epidemiology and Health Data Insights.2026; 2(3): ehdi035. CrossRef
Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population
Dima Kreidieh, Rouba Ballout, Rana Abutaima, Samer A. Kharroubi, Fatima A. Saleh
BMC Public Health.2026;[Epub] CrossRef
A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies
Iman Saad Ahmed, Sara Luay Tapponi, Hala Malek Manaa, Amina Soltani, Elzahraa Shehata Hussein, Fatemeh Ali Parvaresh, Zahid Hussain, Jasbir Arora (RSS)
Journal of Obesity.2026;[Epub] CrossRef
The case for primary prevention of obesity in the era of GLP-1 therapies
Søren Holm, Manuel Tena-Sempere, Dimitrios Koutsouris, George V. Dedoussis, Karl-Heinz Wagner, Sara Arranz, Philippe Froguel, Torsten Bohn, Paulo J. Oliveira, Jeroen Lakerveld, Aakruti Kaikini, Achim Kramer, Adam Selamnia, Adina Weinberger, Adrian Jauch,
The Lancet Regional Health - Europe.2026; 66: 101679. CrossRef
The neuro-metabolic epidemic and the CB1R paradox
Francesca Vaccaro, Ginevra Malta, Manfredi Rizzo, Fulvio Plescia, Gianluca Lavanco
Current Opinion in Pharmacology.2026; 89: 102631. CrossRef
Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis
Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Wafaa Ramadan Ahmed, Khalid Hamid Fadul
INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2026;[Epub] CrossRef
GIPR:GCGR co-agonism restores normal weight in obese rodents
Diego Perez-Tilve, Fa Zhang, Yujin Zhang, Kaitlyn Lohman, Joyce Sorrell, Andrew Vick, Timo D. Müller, Matthias H. Tschöp, Richard D. DiMarchi
Molecular Metabolism.2026; 108: 102365. CrossRef
Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation
Ying-Ru Chen, Zheng-Hong Jiang, Jui-Yi Chen, Vin-Cent Wu
GeroScience.2026;[Epub] CrossRef
The Gastrointestinal Safety of Orforglipron, a GLP‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Abdallfatah Abdallfatah, Mohamed Reyad Mohamed, Amira Fahmy El‐Nemr, Odai Maihoub, Ahmed Elsekhary, Safir Eladawi, Biruk Demisse Ayalew, Ahmed Mansour, Ayoup Ahmed Radi, Mohamed Abuelazm, Mohamed
Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
Tirzepatide versus Semaglutide: Selecting the Right Agent for the Right Patient in Contemporary Metabolic Care
Ahmad Alam
Bangladesh Journal of Endocrinology and Metabolism.2026;[Epub] CrossRef
Systematic Characterisation of GLP‐1R in Human Enteric Nervous System: Implications for GLP‐1 as a Key Regulator of Colonic Activity
Kiran Devi Dontamsetti, Rubina Aktar, Madusha Peiris
Journal of Neurochemistry.2026;[Epub] CrossRef
Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis
Po-Lung Cheng, Hua-Ching Chang
Diabetes Research and Clinical Practice.2026; 237: 113333. CrossRef
Unexpected Therapeutic Effect of GLP-1 Receptor Agonists in Patients With Refractory IBS-D: A Case Series
Solangel Isabelle Suarez, Bilori Bilori, Sai Venkat Aluri, Saurav Das
Annals of Internal Medicine: Clinical Cases.2026;[Epub] CrossRef
Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists
Maria-Daniela Tanasescu, Andrei-Mihnea Rosu, Alexandru Minca, Maria-Mihaela Grigorie, Delia Timofte, Dorin Ionescu
Life.2026; 16(5): 756. CrossRef
Microneedles (MNs)-based technology for diabetes management: design, delivery, and artificial intelligence integration
Fuad Saleh, Zakarya A.M. Hazaea, Mansour Alantry Abdu, Waleed Alahmad, Mohammad Ashfaq
Inorganic Chemistry Communications.2026; 190: 116931. CrossRef
Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications
Cici McGuane, Nosha Farhadhar, Khavir A Sharieff, Stephanie N Petrosky, Karima Alabasi
Cureus.2026;[Epub] CrossRef
New Avenues in Adjunctive Pharmacotherapy for Substance Use Disorders
David Crockford, Anees Bahji
Canadian Journal of Addiction.2026; 17(2): 4. CrossRef
Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance
Raynier Zambrano-Villacres, Martín Campuzano-Donoso, Claudia Reytor-González, Gianluca Rossetti, Luigi Cobellis, Francesco Cobellis, Vincenzo Pilone, Daniel Simancas-Racines, Luigi Schiavo
Nutrients.2026; 18(11): 1751. CrossRef
Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies
Chung-woo Lee
Korean Journal of Family Practice.2026; 16(2): 81. CrossRef
GLP‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study
Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, Bo‐Yeon Kim, Chang Won Jeong, Dae‐Yeon Kim, Hang A Park, Min‐Ho Kim, Seong Hwan Kim, Won‐Woo Seo, Woo Jin Kim, Young Sung Suh, Ra
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study
Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care
Paola Mogna-Peláez, Marta Guasch-Ferré
The Journal of Nutrition.2026; 156(8): 101684. CrossRef
Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam
Sleep Medicine.2025; 134: 106709. CrossRef
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Shikha Patel, Sarfaraz K. Niazi
Pharmaceutics.2025; 17(8): 1036. CrossRef
GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli, Andrea Fagiolini
Life.2025; 15(9): 1422. CrossRef
Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng
Frontiers in Endocrinology.2025;[Epub] CrossRef
Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
Diabetes & Metabolism Journal.2025; 49(6): 1331. CrossRef
Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
Ralf Weiskirchen, Amedeo Lonardo
Medical Sciences.2025; 13(4): 265. CrossRef
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Ki Hoon Kwak, Chang Hee Jung
Endocrinology and Metabolism.2025; 40(6): 879. CrossRef
Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
琳娜勾
Advances in Clinical Medicine.2025; 15(12): 2047. CrossRef

Short Communication

Technology/Device
Comparison of Laser and Conventional Lancing Devices for Blood Glucose Measurement Conformance and Patient Satisfaction in Diabetes Mellitus: Jung A Kim, Min Jeong Park, Eyun Song, Eun Roh, So Young Park, Da Young Lee, Jaeyoung Kim, Ji Hee Yu, Ji A Seo, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo, Nan Hee Kim; Diabetes Metab J. 2022;46(6):936-940. Published online March 30, 2022; DOI: https://doi.org/10.4093/dmj.2021.0293

12,014 View
324 Download
6 Web of Science
6 Crossref

Abstract PDF PubReader ePub

Self-monitoring of capillary blood glucose is important for controlling diabetes. Recently, a laser lancing device (LMT-1000) that can collect capillary blood without skin puncture was developed. We enrolled 150 patients with type 1 or 2 diabetes mellitus. Blood sampling was performed on the same finger on each hand using the LMT-1000 or a conventional lancet. The primary outcome was correlation between glucose values using the LMT-1000 and that using a lancet. And we compared the pain and satisfaction of the procedures. The capillary blood sampling success rates with the LMT-1000 and lancet were 99.3% and 100%, respectively. There was a positive correlation (r=0.974, P<0.001) between mean blood glucose levels in the LMT-1000 (175.8±63.0 mg/dL) and conventional lancet samples (172.5±63.6 mg/dL). LMT-1000 reduced puncture pain by 75.0% and increased satisfaction by 80.0% compared to a lancet. We demonstrated considerable consistency in blood glucose measurements between samples from the LMT-1000 and a lancet, but improved satisfaction and clinically significant pain reduction were observed with the LMT-1000 compared to those with a lancet.

Citations

Citations to this article as recorded by

Laser-Assisted Self-Monitoring of Blood Glucose: Analytical Performance, Clinical Accuracy, and Usability of the HandyRay-Glu System
Minsup Lim, JunMin Lee, Ji A Seo, Sun-Young Ko
Diagnostics.2026; 16(11): 1700. CrossRef
Clinical effectiveness and safety of laser lancing for heel puncture in preterm infants: a randomized crossover non-inferiority trial
Chul Kyu Yun, Hye Won Cho, Eui Kyung Choi, Jaeyoung Kim, Hyung Jin Kim, Byung Chul Park, Byung Min Choi
Journal of Perinatology.2026;[Epub] CrossRef
Pain-Related Responses in Preterm Babies Using Automated and Laser Heel-Lancing Devices
Hea Jin Lee, Myoung Soo Kim, Mi Lim Chung
Creative Nursing.2025; 31(2): 190. CrossRef
Capillary blood glucose testing by paramedics
Pete Gregory
Journal of Paramedic Practice.2025; 17(11): 446. CrossRef
Comparison between a laser-lancing device and automatic incision lancet for capillary blood sampling from the heel of newborn infants: a randomized feasibility trial
Chul Kyu Yun, Eui Kyung Choi, Hyung Jin Kim, Jaeyoung Kim, Byung Cheol Park, Kyuhee Park, Byung Min Choi
Journal of Perinatology.2024; 44(8): 1193. CrossRef
Comparison of laser and traditional lancing devices for capillary blood sampling in patients with diabetes mellitus and high bleeding risk
Min Jeong Park, Soon Young Hwang, Ahreum Jang, Soo Yeon Jang, Eyun Song, So Young Park, Da Young Lee, Jaeyoung Kim, Byung Cheol Park, Ji Hee Yu, Ji A Seo, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo, Nan Hee Kim
Lasers in Medical Science.2024;[Epub] CrossRef

Original Articles

Cardiovascular Risk/Epidemiology
Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study: You-Bin Lee, Minji Koo, Eunjin Noh, Soon Young Hwang, Jung A Kim, Eun Roh, So-hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo; Diabetes Metab J. 2022;46(5):722-732. Published online March 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0225

17,045 View
419 Download
10 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We assessed the myocardial infarction (MI), stroke, and all-cause death risks during follow-up according to the low-density lipoprotein cholesterol (LDL-C) levels among older adults.
Methods
The Korean National Health Insurance Service datasets (2002 to 2020) were used for this population-based cohort study. The hazards of MI, stroke, and all-cause mortality during follow-up were analyzed according to LDL-C level in individuals aged ≥65 years without baseline cardiovascular diseases (n=1,391,616).
Results
During a mean 7.55 years, 52,753 MIs developed; 84,224 strokes occurred over a mean 7.47 years. After a mean 8.50 years, 233,963 died. A decrease in LDL-C was associated with lower hazards of MI and stroke. The decreased hazard of stroke in lower LDL-C was more pronounced in statin users, and individuals with diabetes or obesity. The hazard of all-cause death during follow-up showed an inverted J-shaped pattern according to the LDL-C levels. However, the paradoxically increased hazard of mortality during follow-up in lower LDL-C was attenuated in statin users and individuals with diabetes, hypertension, or obesity. In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.
Conclusion
Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.

Citations

Citations to this article as recorded by

Low atherogenic index of plasma is associated with spontaneous hemorrhagic transformation in acute ischemic stroke patients: a retrospective cohort study and predictive modeling based on machine learning
Kaige Xuan, Yu Guo, Peng Li, Luxuan Liu, Deguo Meng, Zichun Wei, Qi Xiao, Rongyao Hou, Xiaoyan Zhu
Lipids in Health and Disease.2026;[Epub] CrossRef
Distribution of LDL-Cholesterol Levels and Their Associations With Cardiovascular Outcomes in Young Adults Under 40 Years in South Korea: A Nationwide Cohort Study
You-Bin Lee, Kyu-Na Lee, Kyungdo Han
Journal of Lipid and Atherosclerosis.2026; 15(2): 328. CrossRef
Low-density lipoprotein cholesterol and clinical outcomes in patients with liver cirrhosis: a nationwide cohort study
Byung Sik Kim, Jiyeong Kim, Nayeon Choi, Hyun-Jin Kim, Jeong-Hun Shin
Annals of Medicine.2025;[Epub] CrossRef
Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study
Ji Eun Jun, In-Kyung Jeong, Kyu Jeong Ahn, Ho Yeon Chung, You-Cheol Hwang
European Journal of Preventive Cardiology.2024; 31(10): 1205. CrossRef
Associations of Low-density Lipoprotein Cholesterol With All-cause and Cause-specific Mortality in Older Adults in China
Wenqing Ni, Yuebin Lv, Xueli Yuan, Yan Zhang, Hongmin Zhang, Yijing Zheng, Xiaoming Shi, Jian Xu
The Journal of Clinical Endocrinology & Metabolism.2024; 110(1): e132. CrossRef
Risk Factors of Acute Ischemic Stroke and Mortality Among Adults With Endocardial Fibroelastosis
Talal Warsi, Kamleshun Ramphul, Mansimran Singh Dulay, Saddam Jeelani, Renuka Verma, Nomesh Kumar, Jasninder Singh Dhaliwal, Caleb Carver, Hemamalini Sakthivel, Syed Khurram Mushtaq Gardezi, Saurabh Deshpande, Akil A. Sherif, Alexander Liu, Raheel Ahmed
The Neurologist.2024; 29(6): 317. CrossRef
A Look at Primary and Secondary Prevention in the Elderly: The Two Sides of the Same Coin
Maurizio Giuseppe Abrignani, Fabiana Lucà, Vincenzo Abrignani, Giuseppe Pelaggi, Alessandro Aiello, Furio Colivicchi, Francesco Fattirolli, Michele Massimo Gulizia, Federico Nardi, Paolo Giuseppe Pino, Iris Parrini, Carmelo Massimiliano Rao
Journal of Clinical Medicine.2024; 13(15): 4350. CrossRef
Contradictions in traditional ideas about atherosclerosis and the efficacy of lipid-lowering therapy. Promising directions
A. P. Vasiliev, N. N. Streltsova
Сибирский научный медицинский журнал.2024; 44(4): 38. CrossRef
The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study
Chin-Huan Chang, Shu-Tin Yeh, Seng-Wei Ooi, Chung-Yi Li, Hua-Fen Chen
PeerJ.2023; 11: e14609. CrossRef
ERCC1 polymorphism and its expression associated with ischemic stroke in Chinese population
Xiao-Dong Deng, Jian-Lin Ke, Tai-Yu Chen, Qin Gao, Zhuo-Lin Zhao, Wei Zhang, Huan Liu, Ming-Liang Xiang, Li-Zhen Wang, Ying Ma, Yun Liu
Frontiers in Neurology.2023;[Epub] CrossRef
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes & Metabolism Journal.2022; 46(4): 517. CrossRef
Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
Endocrinology and Metabolism.2022; 37(5): 759. CrossRef

Metabolic Risk/Epidemiology
Age- and Sex-Related Differential Associations between Body Composition and Diabetes Mellitus: Eun Roh, Soon Young Hwang, Jung A Kim, You-Bin Lee, So-hyeon Hong, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo; Diabetes Metab J. 2021;45(2):183-194. Published online June 16, 2020; DOI: https://doi.org/10.4093/dmj.2019.0171

12,622 View
276 Download
6 Web of Science
10 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background

The age- and sex-related differences on the impacts of body composition on diabetes mellitus (DM) remain uncertain.

Methods

The fourth and fifth Korea National Health and Nutrition Examination Survey included 15,586 subjects over 30 years of age who completed dual-energy X-ray absorptiometry. We conducted a cross-sectional study to investigate whether muscle mass index (MMI), defined as appendicular skeletal muscle divided by body mass index (BMI), and fat mass index (FMI), defined as trunk fat mass divided by BMI, were differently associated with DM according to age and sex.

Results

In multivariate logistic regression, the risk for DM significantly increased across quartiles of FMI in men aged ≥70. Meanwhile, MMI showed a protective association with DM in men of the same age. The odds ratios (ORs) for the highest quartile versus the lowest quartile of FMI and MMI were 3.116 (95% confidence interval [CI], 1.405 to 6.914) and 0.295 (95% CI, 0.157 to 0.554), respectively. In women, the ORs of DM was significantly different across FMI quartiles in those over age 50. The highest quartile of FMI exhibited increased ORs of DM in subjects aged 50 to 69 (OR, 1.891; 95% CI, 1.229 to 2.908) and ≥70 (OR, 2.275; 95% CI, 1.103 to 4.69) compared to lowest quartile. However, MMI was not significantly associated with DM in women of all age groups.

Conclusion

Both FMI and MMI were independent risk factors for DM in men aged 70 years or more. In women over 50 years, FMI was independently associated with DM. There was no significant association between MMI and DM in women.

Citations

Citations to this article as recorded by

Life-course nutrition strategies for Korean middle-aged adults across biological transitions, nutritional burdens, and a community-linked precision nutrition model: a narrative review
Yoo Kyoung Park
Korean Journal of Community Nutrition.2026; 31(3): 215. CrossRef
Associations of four obesity indices with diabetes mellitus in Korean middle-aged and older adults using the Korean Genome and Epidemiology Study (KoGES)
Yiseul Lee, Nam-Kyoo Lim, Hyun-Young Park
BMC Public Health.2025;[Epub] CrossRef
Contrasting associations of body mass index and waist circumference with cancer incidence in the elderly: a nationwide population-based study
Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Min Jeong Park, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Frontiers in Oncology.2025;[Epub] CrossRef
Research Progress on Type 2 Diabetes with Sarcopenia and Glycemic Stability
静孙
Journal of Clinical Personalized Medicine.2025; 04(06): 141. CrossRef
Research Progress on Correlation between Body Composition Changes and Disease Pro-gression of Type 2 Diabetes
敏张
Advances in Clinical Medicine.2024; 14(03): 936. CrossRef
Associations of the fat-free mass index and the fat mass index with the risk of developing diabetes and prediabetes in US adults: a nationally representative cross-sectional study
Da Liu, You-Lan Lei, Li Zhang, Wenyao Wang, Chunli Shao, Qing Zhou, Haiping Liu, Jun Wen, Jingjia Wang, Chen Li, Yiming Luo, Jingxin Rao, Yukun Shi, Gang Liu, Jie Yang, Mingqi Zheng, Yi-Da Tang
Lipids in Health and Disease.2024;[Epub] CrossRef
Low Skeletal Muscle Mass Accompanied by Abdominal Obesity Additively Increases the Risk of Incident Type 2 Diabetes
Ji Eun Jun, Seung-Eun Lee, You-Bin Lee, Gyuri Kim, Sang-Man Jin, Jae Hwan Jee, Jae Hyeon Kim
The Journal of Clinical Endocrinology & Metabolism.2023; 108(5): 1173. CrossRef
Is imaging-based muscle quantity associated with risk of diabetes? A meta-analysis of cohort studies
Shanhu Qiu, Xue Cai, Yang Yuan, Bo Xie, Zilin Sun, Tongzhi Wu
Diabetes Research and Clinical Practice.2022; 189: 109939. CrossRef
Whole and segmental body composition changes during mid-follicular and mid-luteal phases of the menstrual cycle in recreationally active young women
Şükran Nazan Koşar, Yasemin Güzel, Mehmet Gören Köse, Ayşe Kin İşler, Tahir Hazır
Annals of Human Biology.2022; 49(2): 124. CrossRef
Body Composition and Diabetes
Hye Jin Yoo
The Journal of Korean Diabetes.2021; 22(4): 238. CrossRef

Obesity and Metabolic Syndrome
Proportion and Characteristics of the Subjects with Low Muscle Mass and Abdominal Obesity among the Newly Diagnosed and Drug-Naïve Type 2 Diabetes Mellitus Patients: Jung A Kim, Soon Young Hwang, Hye Soo Chung, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo; Diabetes Metab J. 2019;43(1):105-113. Published online September 28, 2018; DOI: https://doi.org/10.4093/dmj.2018.0036

10,689 View
109 Download
20 Web of Science
22 Crossref

Abstract PDF PubReader ePub

Background

Sarcopenic obesity (SO) is a serious public health concern, few studies have examined the clinical implications of SO in newly-diagnosed type 2 diabetes mellitus (T2DM) patients. We evaluated the prevalence of the newly diagnosed, drug-naïve T2DM patients with low muscle mass with abdominal obesity and its association with insulin resistance and other diabetic complications.

Methods

We classified 233 drug-naïve T2DM subjects into four groups according to abdominal obesity (waist circumference ≥90 cm in men and ≥85 cm in women) and low muscle mass status (appendicular skeletal muscle <7.0 kg/m² for men and <5.4 kg/m² for women).

Results

The proportion of the subjects with low muscle mass and abdominal obesity among the newly diagnosed, drug-naïve T2DM patients was 8.2%. Homeostasis model assessment of insulin resistance (HOMA-IR) increased linearly according to body composition group from normal to abdominal obesity to both low muscle mass and abdominal obesity. The multiple logistic regression analysis indicated that subjects with low muscle mass and abdominal obesity (odds ratio [OR], 9.39; 95% confidence interval [CI], 2.41 to 36.56) showed a higher risk for insulin resistance, defined as HOMA-IR ≥3, than those with abdominal obesity (OR, 5.36; 95% CI, 2.46 to 11.69), even after adjusting for other covariates. However, there were no differences in lipid profiles, microalbuminuria, or various surrogate markers for atherosclerosis among the four groups.

Conclusion

Subjects with both low muscle mass and abdominal obesity had a higher risk of insulin resistance than those with low muscle mass or abdominal obesity only.

Citations

Citations to this article as recorded by

Higher Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Associated With Reduced Risk of Prediabetes
Haiyan Yang, Wen Zhong, Shuhui Shen, Yang Gao, Xiangqin Fu, Sheng Ge, Shuyao Hua, Tong Zou
Diabetes, Obesity and Metabolism.2026; 28(7): 6254. CrossRef
Association between sarcopenic obesity and mild cognitive impairment in patients with type 2 diabetes mellitus
Lei Zhang, Yonghong Cao, Yueyu Zhang, Wu Dai, Xin Wu, Jiajia Song, Dechao Yin, Xiaofang Han
Frontiers in Nutrition.2026;[Epub] CrossRef
Exploring the relationship between glycemic variability and muscle dysfunction in adults with diabetes: A systematic review
Shanshan Lin, Sof Andrikopoulos, Yan-Chuan Shi, David Sibbritt, Wenbo Peng
Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 837. CrossRef
Relationship Between Fat-to-Muscle Ratio and Nonalcoholic Fatty Liver Disease in Middle-Aged and Older Adults with Type 2 Diabetes: Cross-Sectional Study
Lei Zhang, Yulu Sun, Yiran Zhao, Xin Wu, Xiaofang Han
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2067. CrossRef
Muscle-building interventions improve glucose metabolism in elderly type 2 diabetic patients with sarcopenic obesity
Tingting Han, Xinyue Liang, Hongxia Liu, Mingyu Zhu, Sisi Shen, Jia Song, Hongwei Chen, Ningxin Chen, Yue Liu, Ziyi Wei, Yurong Weng, Xian Jin, Yaomin Hu
Nutrition & Metabolism.2025;[Epub] CrossRef
Research Progress on the Association Between Sarcopenic Obesity and Atherosclerosis: Current Status and Challenges
Kai Yang, Wei Yang, Si-Cong Si, Jia Liu, Yi-Xin Ma, Huan Zhao
Journal of Clinical Medicine.2025; 14(22): 8148. CrossRef
Coexistence of high visceral fat area and sarcopenia is associated with atherosclerotic markers in old‐old patients with diabetes: A cross‐sectional study
Motoya Sato, Yoshiaki Tamura, Yuji Murao, Fumino Yorikawa, Yuu Katsumata, So Watanabe, Shugo Zen, Remi Kodera, Kazuhito Oba, Kenji Toyoshima, Yuko Chiba, Atsushi Araki
Journal of Diabetes Investigation.2024; 15(10): 1510. CrossRef
The coexistence of low muscle mass and obesity evaluated by dual energy X‐ray absorptiometry, rather than low muscle mass or obesity alone, is associated with macrovascular but not microvascular complications in patients with type 2 diabetes mellitus
Han Li, Weijuan Su, Zeyu Zheng, Jia Li, Shunhua Wang, Zheng Chen, Yuxian Zhang, Bingkun Huang, Fuping Lyu, Fangfang Yan, Caoxin Huang, Mingzhu Lin, Xiulin Shi, Xuejun Li
Diabetes, Obesity and Metabolism.2024; 26(12): 6034. CrossRef
Clinical observation on acupuncture for 80 patients with abdominal obesity in Germany: based on the theory of unblocking and regulating the Belt Vessel
Yuanyuan Li, Hang Xiong, Shuhui Ma, Jingzhang Dai
Journal of Acupuncture and Tuina Science.2023; 21(2): 137. CrossRef
Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585. CrossRef
Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement
Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Kentaro Azuma, Kazuya Murata
Endocrine Journal.2023; 70(6): 591. CrossRef
A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus
Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Journal of Obesity & Metabolic Syndrome.2023; 32(2): 130. CrossRef
Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis
Yuan-yuan Zhou, Jin-feng Wang, Qian Yao, Qiu-feng Jian, Zhi-peng Luo
Clinical Nutrition ESPEN.2023; 58: 128. CrossRef
The Correlation Between Leg Muscle Mass Index and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
Menggege Liu, Qing Zhang, Juan Liu, Huiling Bai, Ping Yang, Xinhua Ye, Xiaoqing Yuan
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4169. CrossRef
Sarcopenic Obesity with Normal Body Size May Have Higher Insulin Resistance in Elderly Patients with Type 2 Diabetes Mellitus
Tingting Han, Ting Yuan, Xinyue Liang, Ningxin Chen, Jia Song, Xin Zhao, Yurong Weng, Yaomin Hu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1197. CrossRef
Relationship between Visceral Adipose Index, Lipid Accumulation Product and Type 2 Diabetes Mellitus
停停陈
Advances in Clinical Medicine.2022; 12(04): 3350. CrossRef
Assessment of the relationship between prediabetes and low skeletal mass based on blood creatinine level
S. I. Ibragimova, G. O. Nuskabayeva, Z. N. Shalkharova, K. Zh. Sadykova, G. A. Junusbekova, M. Oran
Diabetes mellitus.2022; 25(3): 226. CrossRef
Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross‐sectional study
Yasushi Imamura, Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Yasunari Hiramine, Akiko Saishoji, Atsuko Kakihara, Mai Nakahara, Manei Oku, Kaori Hosoyamada, Shuji Kanmura, Akihiro Moriuchi, Hironori Miyahara, Akio ido
Hepatology Research.2021; 51(5): 570. CrossRef
Body Composition and Diabetes
Hye Jin Yoo
The Journal of Korean Diabetes.2021; 22(4): 238. CrossRef
Reduced Skeletal Muscle Volume and Increased Skeletal Muscle Fat Deposition Characterize Diabetes in Individuals after Pancreatitis: A Magnetic Resonance Imaging Study
Andre E. Modesto, Juyeon Ko, Charlotte E. Stuart, Sakina H. Bharmal, Jaelim Cho, Maxim S. Petrov
Diseases.2020; 8(3): 25. CrossRef
Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross‐sectional study in Korea
Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
Geriatrics & Gerontology International.2020; 20(4): 271. CrossRef
Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis
Dima Khadra, Leila Itani, Hana Tannir, Dima Kreidieh, Dana El Masri, Marwan El Ghoch
World Journal of Diabetes.2019; 10(5): 311. CrossRef

First
Prev
Page of 1
Next
Last

Search